Female fertility preservation for family planning: a position statement of the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR).
Family planning
Fertility preservation
Oocytes cryopreservation
Ovarian reserve
Journal
Journal of assisted reproduction and genetics
ISSN: 1573-7330
Titre abrégé: J Assist Reprod Genet
Pays: Netherlands
ID NLM: 9206495
Informations de publication
Date de publication:
20 Jul 2024
20 Jul 2024
Historique:
received:
09
04
2024
accepted:
03
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
19
7
2024
Statut:
aheadofprint
Résumé
This position statement by the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) aims to establish an optimal framework for fertility preservation outside the standard before oncological therapies. Key topics include the role of fertility units in comprehensive fertility assessment, factors impacting ovarian potential, available preservation methods, and appropriate criteria for offering such interventions. The SIFES-MR writing group comprises Italian reproductive physicians, embryologists, and scientists. The consensus emerged after a six-month period of meetings, including extensive literature review, dialogue among authors and input from society members. Final approval was granted by the SIFES-MR governing council. Fertility counselling transitions from urgent to long-term care, emphasizing family planning. Age, along with ovarian reserve markers, is the primary predictor of female fertility. Various factors, including gynecological conditions, autoimmune disorders, and prior gonadotoxic therapies, may impact ovarian reserve. Oocyte cryopreservation should be the preferred method. Women 30-34 years old and 35-39 years old, without known pathologies impacting the ovarian reserve, should cryopreserve at least 12-13 and 15-20 oocytes to achieve the same chance of a spontaneous live birth they would have if they tried to conceive at the age of cryopreservation (63% and 52%, respectively in the two age groups). Optimal fertility counselling necessitates a long-term approach, that nurtures an understanding of fertility, facilitates timely evaluation of factors that may affect fertility, and explores fertility preservation choices at opportune intervals.
Identifiants
pubmed: 39030346
doi: 10.1007/s10815-024-03197-4
pii: 10.1007/s10815-024-03197-4
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
ISTAT. Indicatori demografici, anno 2023. 2023. [Online]. Available: https://www.istat.it/it/files//2023/12/CENSIMENTOEDINAMICADEMOGRAFICA2022.pdf . Accessed 20 Jan 2024.
European IVF Monitoring Consortium (EIM), for the European Society of Human Reproduction and Embryology (ESHRE), et al. ART in Europe, 2018: results generated from European registries by ESHRE. Hum Reprod Open. 2022;2022(3): hoac022. https://doi.org/10.1093/hropen/hoac022 .
Harper JC, et al. Feasibility and acceptability of theatrical and visual art to deliver fertility education to young adults. Hum Fertil Camb Engl. 2021;24(2):129–35. https://doi.org/10.1080/14647273.2019.1570354 .
doi: 10.1080/14647273.2019.1570354
Hodes-Wertz B, Druckenmiller S, Smith M, Noyes N. What do reproductive-age women who undergo oocyte cryopreservation think about the process as a means to preserve fertility? Fertil Steril. 2013;100(5):1343–9. https://doi.org/10.1016/j.fertnstert.2013.07.201 .
doi: 10.1016/j.fertnstert.2013.07.201
pubmed: 23953326
Cimadomo D, Fabozzi G, Vaiarelli A, Ubaldi N, Ubaldi FM, Rienzi L. Impact of maternal age on oocyte and embryo competence. Front Endocrinol. 2018;9:327. https://doi.org/10.3389/fendo.2018.00327 .
doi: 10.3389/fendo.2018.00327
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006;12(6):Art. no. 6. https://doi.org/10.1093/humupd/dml034 .
doi: 10.1093/humupd/dml034
Miller CM, Melikian REM, Jones TL, Purdy MP, Khan Z, Bleess JL, Stewart EA, Coddington CC, Shenoy CC. Follicle Stimulating Hormone (FSH) as a Predictor of Decreased Oocyte Yield in Patients with Normal Anti-Müllerian Hormone (AMH) and Antral Follicle Count (AFC). J Reprod Infertil. 2023;24(3):181–7. https://doi.org/10.18502/jri.v24i3.13274 .
doi: 10.18502/jri.v24i3.13274
pubmed: 37663421
pmcid: 10471944
Biniasch M, Laubender RP, Hund M, Buck K, De Geyter C. Intra- and inter-cycle variability of anti-Müllerian hormone (AMH) levels in healthy women during non-consecutive menstrual cycles: the BICYCLE study. Clin Chem Lab Med. 2022;60(4):Art. no. 4. https://doi.org/10.1515/cclm-2021-0698 .
doi: 10.1515/cclm-2021-0698
Liu Y, Pan Z, Wu Y, Song J, Chen J. Comparison of anti-Müllerian hormone and antral follicle count in the prediction of ovarian response: a systematic review and meta-analysis. J Ovarian Res. 2023;16(1):Art. no. 1. https://doi.org/10.1186/s13048-023-01202-5 .
doi: 10.1186/s13048-023-01202-5
Dutta S, et al. Reproductive toxicity of combined effects of endocrine disruptors on human reproduction. Front Cell Dev Biol. 2023;11:1162015. https://doi.org/10.3389/fcell.2023.1162015 .
doi: 10.3389/fcell.2023.1162015
pubmed: 37250900
pmcid: 10214012
Dechanet C, et al. Effects of cigarette smoking on reproduction. Hum Reprod Update. 2011;17(1):Art. no. 1. https://doi.org/10.1093/humupd/dmq033 .
doi: 10.1093/humupd/dmq033
de Angelis C, et al. Smoke, alcohol and drug addiction and female fertility. Reprod Biol Endocrinol RBE. 2020;18(1):Art. no. 1. https://doi.org/10.1186/s12958-020-0567-7 .
doi: 10.1186/s12958-020-0567-7
Lo JO, D’Mello RJ, Watch L, Schust DJ, Murphy SK. An epigenetic synopsis of parental substance use. Epigenomics. 2023;15(7):Art. no. 7. https://doi.org/10.2217/epi-2023-0064 .
doi: 10.2217/epi-2023-0064
Wang W, Hafner KS, Flaws JA. In utero bisphenol A exposure disrupts germ cell nest breakdown and reduces fertility with age in the mouse. Toxicol Appl Pharmacol. 2014;276(2):Art. no. 2. https://doi.org/10.1016/j.taap.2014.02.009 .
doi: 10.1016/j.taap.2014.02.009
Santulli P, et al. Fertility preservation in women with benign gynaecological conditions. Hum Reprod Open. 2023;2023(2):hoad012. https://doi.org/10.1093/hropen/hoad012 .
doi: 10.1093/hropen/hoad012
pubmed: 37124950
pmcid: 10130191
Busacca M, et al. Postsurgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol. 2006;195(2):Art. no. 2. https://doi.org/10.1016/j.ajog.2006.03.064 .
doi: 10.1016/j.ajog.2006.03.064
Garcia-Velasco JA, Somigliana E. Management of endometriomas in women requiring IVF: to touch or not to touch. Hum Reprod Oxf Engl. 2009;24(3):Art. no. 3. https://doi.org/10.1093/humrep/den398 .
doi: 10.1093/humrep/den398
Uncu G, Kasapoglu I, Ozerkan K, Seyhan A, Oral Yilmaztepe A, Ata B. Prospective assessment of the impact of endometriomas and their removal on ovarian reserve and determinants of the rate of decline in ovarian reserve. Hum Reprod Oxf Engl. 2013;28(8):2140–5. https://doi.org/10.1093/humrep/det123 .
doi: 10.1093/humrep/det123
Takeuchi A, et al. Endometriosis triggers excessive activation of primordial follicles via PI3K-PTEN-Akt-Foxo3 pathway. J Clin Endocrinol Metab. 2019;104(11):Art. no. 11. https://doi.org/10.1210/jc.2019-00281 .
doi: 10.1210/jc.2019-00281
Sanchez AM, Viganò P, Somigliana E, Panina-Bordignon P, Vercellini P, Candiani M. The distinguishing cellular and molecular features of the endometriotic ovarian cyst: from pathophysiology to the potential endometrioma-mediated damage to the ovary. Hum Reprod Update. 2014;20(2):217–30. https://doi.org/10.1093/humupd/dmt053 .
doi: 10.1093/humupd/dmt053
pubmed: 24129684
Cobo A, Giles J, Paolelli S, Pellicer A, Remohí J, García-Velasco JA. Oocyte vitrification for fertility preservation in women with endometriosis: an observational study. Fertil Steril. 2020;113(4):Art. no. 4. https://doi.org/10.1016/j.fertnstert.2019.11.017 .
doi: 10.1016/j.fertnstert.2019.11.017
Vaiarelli A, et al. Endometriosis shows no impact on the euploid blastocyst rate per cohort of inseminated metaphase-II oocytes: a case-control study. Eur J Obstet Gynecol Reprod Biol. 2021;256:205–10. https://doi.org/10.1016/j.ejogrb.2020.11.024 .
doi: 10.1016/j.ejogrb.2020.11.024
pubmed: 33246206
Cobo A, et al. Number needed to freeze: cumulative live birth rate after fertility preservation in women with endometriosis. Reprod Biomed Online. 2021;42(4):725–32. https://doi.org/10.1016/j.rbmo.2020.12.013 .
doi: 10.1016/j.rbmo.2020.12.013
pubmed: 33573907
Knaus ME, et al. Recurrence rates for pediatric benign ovarian neoplasms. J Pediatr Adolesc Gynecol. 2023;36(2):Art. no. 2. https://doi.org/10.1016/j.jpag.2022.11.006 .
doi: 10.1016/j.jpag.2022.11.006
Atwi D, Kamal M, Quinton M, Hassell LA. Malignant transformation of mature cystic teratoma of the ovary. J Obstet Gynaecol Res. 2022;48(12):3068–76. https://doi.org/10.1111/jog.15409 .
doi: 10.1111/jog.15409
pubmed: 36053141
Angum F, Khan T, Kaler J, Siddiqui L, Hussain A. The prevalence of autoimmune disorders in women: a narrative review. Cureus. 2020;12(5):Art. no. 5. https://doi.org/10.7759/cureus.8094 .
doi: 10.7759/cureus.8094
Khizroeva J, et al. Infertility in women with systemic autoimmune diseases. Best Pract Res Clin Endocrinol Metab. 2019;33(6):Art. no. 6. https://doi.org/10.1016/j.beem.2019.101369 .
doi: 10.1016/j.beem.2019.101369
Somers EC. Pregnancy and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2020;64:3–10. https://doi.org/10.1016/j.bpobgyn.2019.11.004 .
doi: 10.1016/j.bpobgyn.2019.11.004
pubmed: 32173263
Chen JS, Roberts CL, Simpson JM, March LM. Pregnancy outcomes in women with rare autoimmune diseases. Arthritis Rheumatol Hoboken NJ. 2015;67(12):Art. no. 12. https://doi.org/10.1002/art.39311 .
doi: 10.1002/art.39311
Sen A, Kushnir VA, Barad DH, Gleicher N. Endocrine autoimmune diseases and female infertility. Nat Rev Endocrinol. 2014;10(1):Art. no. 1. https://doi.org/10.1038/nrendo.2013.212 .
doi: 10.1038/nrendo.2013.212
Costa M, Colia D. Treating infertility in autoimmune patients. Rheumatol Oxf Engl. 2008;47 Suppl 3:iii38-41. https://doi.org/10.1093/rheumatology/ken156 .
doi: 10.1093/rheumatology/ken156
Szeliga A, et al. Autoimmune diseases in patients with premature ovarian insufficiency-our current state of knowledge. Int J Mol Sci. 2021;22(5):Art. no. 5. https://doi.org/10.3390/ijms22052594 .
doi: 10.3390/ijms22052594
Marder W, Fisseha S, Ganser MA, Somers EC. Ovarian damage during chemotherapy in autoimmune diseases: broad health implications beyond fertility. Clin Med Insights Reprod Health. 2012;2012(6):Art. no. 6. https://doi.org/10.4137/CMRH.S10415 .
doi: 10.4137/CMRH.S10415
Tsuchida Y, et al. Fertility preservation in patients receiving gonadotoxic therapies for systemic autoimmune diseases in Japan. Mod Rheumatol. 2021;31(5):1004–9. https://doi.org/10.1080/14397595.2020.1856020 .
doi: 10.1080/14397595.2020.1856020
pubmed: 33236975
Massarotti C, et al. Menstrual cycle resumption and female fertility after autologous hematopoietic stem cell transplantation for multiple sclerosis. Mult Scler Houndmills Basingstoke Engl. 2021;27(13):2103–7. https://doi.org/10.1177/13524585211000616 .
doi: 10.1177/13524585211000616
Williams A, et al. Obstetric and neonatal complications among women with autoimmune disease. J Autoimmun. 2019;103:102287. https://doi.org/10.1016/j.jaut.2019.05.015 .
doi: 10.1016/j.jaut.2019.05.015
pubmed: 31147159
pmcid: 6708459
Walter IJ, Klein Haneveld MJ, Lely AT, Bloemenkamp KWM, Limper M, Kooiman J. Pregnancy outcome predictors in antiphospholipid syndrome: a systematic review and meta-analysis. Autoimmun Rev. 2021;20(10):102901. https://doi.org/10.1016/j.autrev.2021.102901 .
doi: 10.1016/j.autrev.2021.102901
pubmed: 34280554
Tristano AG. Impact of rheumatoid arthritis on sexual function. World J Orthop. 2014;5(2):Art. no. 2. https://doi.org/10.5312/wjo.v5.i2.107 .
doi: 10.5312/wjo.v5.i2.107
Shigesi N, et al. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum Reprod Update. 2019;25(4):Art. no. 4. https://doi.org/10.1093/humupd/dmz014 .
doi: 10.1093/humupd/dmz014
ESHRE Guideline Group on Female Fertility Preservation, et al. ESHRE guideline: female fertility preservation. Hum Reprod Open. 2020;2020(4): Art. no. 4. https://doi.org/10.1093/hropen/hoaa052 .
ESHRE PGT Consortium Steering Committee, et al. ESHRE PGT Consortium good practice recommendations for the organisation of PGT. Hum Reprod Open. 2020;2020(3):hoaa021. https://doi.org/10.1093/hropen/hoaa021 .
Gawlik A, Malecka-Tendera E. Transitions in endocrinology: treatment of Turner’s syndrome during transition. Eur J Endocrinol. 2014;170(2):Art. no. 2. https://doi.org/10.1530/EJE-13-0900 .
doi: 10.1530/EJE-13-0900
Bernard V, et al. Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. Hum Reprod Oxf Engl. 2016;31(4):782–8. https://doi.org/10.1093/humrep/dew012 .
doi: 10.1093/humrep/dew012
Sarkar R, Marimuthu KM. Association between the degree of mosaicism and the severity of syndrome in Turner mosaics and Klinefelter mosaics. Clin Genet. 1983;24(6):420–8. https://doi.org/10.1111/j.1399-0004.1983.tb00097.x .
doi: 10.1111/j.1399-0004.1983.tb00097.x
pubmed: 6652955
Hagen CP, et al. Serum levels of anti-Müllerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients. J Clin Endocrinol Metab. 2010;95(11):Art. no. 11. https://doi.org/10.1210/jc.2010-0930 .
doi: 10.1210/jc.2010-0930
Hamza RT, Mira MF, Hamed AI, Ezzat T, Sallam MT. Anti-Müllerian hormone levels in patients with turner syndrome: relation to karyotype, spontaneous puberty, and replacement therapy. Am J Med Genet A. 2018;176(9):Art. no. 9. https://doi.org/10.1002/ajmg.a.40473 .
doi: 10.1002/ajmg.a.40473
Huang JYJ, et al. Cryopreservation of ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: case report. Hum Reprod Oxf Engl. 2008;23(2):336–9. https://doi.org/10.1093/humrep/dem307 .
doi: 10.1093/humrep/dem307
Oktay K, Bedoschi G. Oocyte cryopreservation for fertility preservation in postpubertal female children at risk for premature ovarian failure due to accelerated follicle loss in Turner syndrome or cancer treatments. J Pediatr Adolesc Gynecol. 2014;27(6):Art. no. 6. https://doi.org/10.1016/j.jpag.2014.01.003 .
doi: 10.1016/j.jpag.2014.01.003
Oktay K, et al. Fertility preservation in women with turner syndrome: a comprehensive review and practical guidelines. J Pediatr Adolesc Gynecol. 2016;29(5):Art. no. 5. https://doi.org/10.1016/j.jpag.2015.10.011 .
doi: 10.1016/j.jpag.2015.10.011
Practice Committee of American Society for Reproductive Medicine. Increased maternal cardiovascular mortality associated with pregnancy in women with Turner syndrome. Fertil Steril. 2012;97(2):Art. no. 2. https://doi.org/10.1016/j.fertnstert.2011.11.049 .
doi: 10.1016/j.fertnstert.2011.11.049
Sullivan SD, Welt C, Sherman S. FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med. 2011;29(4):Art. no. 4. https://doi.org/10.1055/s-0031-1280915 .
doi: 10.1055/s-0031-1280915
La Marca A, Mastellari E. Fertility preservation for genetic diseases leading to premature ovarian insufficiency (POI). J Assist Reprod Genet. 2021;38(4):Art. no. 4. https://doi.org/10.1007/s10815-021-02067-7 .
doi: 10.1007/s10815-021-02067-7
Nayot D, Chung JT, Son W-Y, Ao A, Hughes M, Dahan MH. Live birth following serial vitrification of embryos and PGD for fragile X syndrome in a patient with the premutation and decreased ovarian reserve. J Assist Reprod Genet. 2013;30(11):Art. no. 11. https://doi.org/10.1007/s10815-013-0079-x .
doi: 10.1007/s10815-013-0079-x
Bibi G, et al. The effect of CGG repeat number on ovarian response among fragile X premutation carriers undergoing preimplantation genetic diagnosis. Fertil Steril. 2010;94(3):Art. no. 3. https://doi.org/10.1016/j.fertnstert.2009.04.047 .
doi: 10.1016/j.fertnstert.2009.04.047
Hipp HS, Charen KH, Spencer JB, Allen EG, Sherman SL. Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI). Menopause N Y N. 2016;23(9):Art. no. 9. https://doi.org/10.1097/GME.0000000000000658 .
doi: 10.1097/GME.0000000000000658
Guerrero NV, Singh RH, Manatunga A, Berry GT, Steiner RD, Elsas LJ. Risk factors for premature ovarian failure in females with galactosemia. J Pediatr. 2000;137(6):Art. no. 6. https://doi.org/10.1067/mpd.2000.109148 .
doi: 10.1067/mpd.2000.109148
Gubbels CS, Land JA, Rubio-Gozalbo ME. Fertility and impact of pregnancies on the mother and child in classic galactosemia. Obstet Gynecol Surv. 2008;63(5):Art. no. 5. https://doi.org/10.1097/OGX.0b013e31816ff6c5 .
doi: 10.1097/OGX.0b013e31816ff6c5
van Erven B, et al. Fertility in adult women with classic galactosemia and primary ovarian insufficiency. Fertil Steril. 2017;108(1):Art. no. 1. https://doi.org/10.1016/j.fertnstert.2017.05.013 .
doi: 10.1016/j.fertnstert.2017.05.013
Mamsen LS, Kelsey TW, Ernst E, Macklon KT, Lund AM, Andersen CY. Cryopreservation of ovarian tissue may be considered in young girls with galactosemia. J Assist Reprod Genet. 2018;35(7):1209–17. https://doi.org/10.1007/s10815-018-1209-2 .
doi: 10.1007/s10815-018-1209-2
pubmed: 29804175
pmcid: 6063818
Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril. 2013;99(1):Art. no. 1. https://doi.org/10.1016/j.fertnstert.2012.09.028 .
doi: 10.1016/j.fertnstert.2012.09.028
Gunnala V, et al. BRCA carriers have similar reproductive potential at baseline to noncarriers: comparisons in cancer and cancer-free cohorts undergoing fertility preservation. Fertil Steril. 2019;111(2):Art. no. 2. https://doi.org/10.1016/j.fertnstert.2018.10.014 .
doi: 10.1016/j.fertnstert.2018.10.014
Titus S, et al. Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med. 2013;5(172):172ra21. https://doi.org/10.1126/scitranslmed.3004925 .
doi: 10.1126/scitranslmed.3004925
pubmed: 23408054
pmcid: 5130338
van Tilborg TC, et al. Serum AMH levels in healthy women from BRCA1/2 mutated families: are they reduced? Hum Reprod Oxf Engl. 2016;31(11):Art. no. 11. https://doi.org/10.1093/humrep/dew242 .
doi: 10.1093/humrep/dew242
Peccatori FA, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod Oxf Engl. 2018;33(2):Art. no. 2. https://doi.org/10.1093/humrep/dex356 .
doi: 10.1093/humrep/dex356
European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod Oxf Engl. 2016; 31(5):Art. no. 5. https://doi.org/10.1093/humrep/dew027 .
De Vos M, Devroey P, Fauser BCJM. Primary ovarian insufficiency. Lancet Lond Engl. 2010;376(9744):Art. no. 9744. https://doi.org/10.1016/S0140-6736(10)60355-8 .
doi: 10.1016/S0140-6736(10)60355-8
Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril. 2016;105(2):459-466.e2. https://doi.org/10.1016/j.fertnstert.2015.10.026 .
doi: 10.1016/j.fertnstert.2015.10.026
pubmed: 26604065
Suzuki N, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod Oxf Engl. 2015;30(3):608–15. https://doi.org/10.1093/humrep/deu353 .
doi: 10.1093/humrep/deu353
Gordon CM, Kanaoka T, Nelson LM. Update on primary ovarian insufficiency in adolescents. Curr Opin Pediatr. 2015;27(4):511–9. https://doi.org/10.1097/MOP.0000000000000236 .
doi: 10.1097/MOP.0000000000000236
pubmed: 26087426
Michala L, Stefanaki K, Loutradis D. Premature ovarian insufficiency in adolescence: a chance for early diagnosis? Horm Athens Greece. 2020;19(3):277–83. https://doi.org/10.1007/s42000-019-00141-5 .
doi: 10.1007/s42000-019-00141-5
Verrilli L, Johnstone E, Welt C, Allen-Brady K. Primary ovarian insufficiency has strong familiality: results of a multigenerational genealogical study. Fertil Steril. 2023;119(1):Art. no. 1. https://doi.org/10.1016/j.fertnstert.2022.09.027 .
doi: 10.1016/j.fertnstert.2022.09.027
Rouen A, et al. Whole exome sequencing in a cohort of familial premature ovarian insufficiency cases reveals a broad array of pathogenic or likely pathogenic variants in 50% of families. Fertil Steril. 2022;117(4):Art. no. 4. https://doi.org/10.1016/j.fertnstert.2021.12.023 .
doi: 10.1016/j.fertnstert.2021.12.023
Venturella R, et al. The genetics of non-syndromic primary ovarian insufficiency: a systematic review. Int J Fertil Steril. 2019;13(3):Art. no. 3. https://doi.org/10.22074/ijfs.2019.5599 .
doi: 10.22074/ijfs.2019.5599
Rossetti R, et al. Targeted next-generation sequencing indicates a frequent oligogenic involvement in primary ovarian insufficiency onset. Front Endocrinol. 2021;12: 664645. https://doi.org/10.3389/fendo.2021.664645 .
doi: 10.3389/fendo.2021.664645
Eskenazi S, et al. Next generation sequencing should be proposed to every woman with “idiopathic” primary ovarian insufficiency. J Endocr Soc. 2021;5(7):Art. no. 7. https://doi.org/10.1210/jendso/bvab032 .
doi: 10.1210/jendso/bvab032
Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010;94(1):Art. no. 1. https://doi.org/10.1016/j.fertnstert.2009.02.043 .
doi: 10.1016/j.fertnstert.2009.02.043
Poirot C, et al. Impact of cancer chemotherapy before ovarian cortex cryopreservation on ovarian tissue transplantation. Hum Reprod Oxf Engl. 2019;34(6):Art. no. 6. https://doi.org/10.1093/humrep/dez047 .
doi: 10.1093/humrep/dez047
Devos M, Diaz Vidal P, Bouziotis J, Anckaert E, Dolmans M-M, Demeestere I. Impact of first chemotherapy exposure on follicle activation and survival in human cryopreserved ovarian tissue. Hum Reprod Oxf Engl. 2023;38(3):Art. no. 3. https://doi.org/10.1093/humrep/dead013 .
doi: 10.1093/humrep/dead013
Pampanini V, et al. Impact of first-line cancer treatment on the follicle quality in cryopreserved ovarian samples from girls and young women. Hum Reprod Oxf Engl. 2019;34(9):Art. no. 9. https://doi.org/10.1093/humrep/dez125 .
doi: 10.1093/humrep/dez125
Arecco L, et al. Safety of fertility preservation techniques before and after anticancer treatments in young women with breast cancer: a systematic review and meta-analysis. Hum Reprod Oxf Engl. 2022;37(5):Art. no. 5. https://doi.org/10.1093/humrep/deac035 .
doi: 10.1093/humrep/deac035
Lambertini M, et al. Pregnancy after breast cancer: a systematic review and meta-analysis. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(29):Art. no. 29. https://doi.org/10.1200/JCO.21.00535 .
doi: 10.1200/JCO.21.00535
Yang W, et al. cyclophosphamide exposure causes long-term detrimental effect of oocytes developmental competence through affecting the epigenetic modification and maternal factors’ transcription during oocyte growth. Front Cell Dev Biol. 2021;9:682060. https://doi.org/10.3389/fcell.2021.682060 .
doi: 10.3389/fcell.2021.682060
pubmed: 34164401
pmcid: 8215553
Lambertini M, et al. Fertility preservation and post-treatment pregnancies in post-pubertal cancer patients: ESMO Clinical Practice Guidelines†. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(12):1664–78. https://doi.org/10.1016/j.annonc.2020.09.006 .
doi: 10.1016/j.annonc.2020.09.006
Vaiarelli A, et al. Luteal phase after conventional stimulation in the same ovarian cycle might improve the management of poor responder patients fulfilling the Bologna criteria: a case series. Fertil Steril. 2020;113(1):Art. no. 1. https://doi.org/10.1016/j.fertnstert.2019.09.012 .
doi: 10.1016/j.fertnstert.2019.09.012
Yang I-J, et al. Usage and cost-effectiveness of elective oocyte freezing: a retrospective observational study. Reprod Biol Endocrinol RBE. 2022;20(1):123. https://doi.org/10.1186/s12958-022-00996-1 .
doi: 10.1186/s12958-022-00996-1
Wafi A, Nekkebroeck J, Blockeel C, De Munck N, Tournaye H, De Vos M. A follow-up survey on the reproductive intentions and experiences of women undergoing planned oocyte cryopreservation. Reprod Biomed Online. 2020;40(2):207–14. https://doi.org/10.1016/j.rbmo.2019.11.010 .
doi: 10.1016/j.rbmo.2019.11.010
pubmed: 31983546
Loreti S, et al. A 10-year follow-up of reproductive outcomes in women attempting motherhood after elective oocyte cryopreservation. Hum Reprod Oxf Engl. 2024;39(2):355–63. https://doi.org/10.1093/humrep/dead267 .
doi: 10.1093/humrep/dead267
Cobo A, García-Velasco J, Domingo J, Pellicer A, Remohí J. Elective and onco-fertility preservation: factors related to IVF outcomes. Hum Reprod Oxf Engl. 2018;33(12):2222–31. https://doi.org/10.1093/humrep/dey321 .
doi: 10.1093/humrep/dey321
Levi Setti PE, et al. Human oocyte cryopreservation with slow freezing versus vitrification. Results from the National Italian Registry data, 2007–2011. Fertil Steril. 2014;102(1):90-95.e2. https://doi.org/10.1016/j.fertnstert.2014.03.052 .
doi: 10.1016/j.fertnstert.2014.03.052
pubmed: 24794316
Mostinckx L, et al. Clinical outcomes from ART in predicted hyperresponders: in vitro maturation of oocytes versus conventional ovarian stimulation for IVF/ICSI. Hum Reprod Oxf Engl. 2024;39(3):586–94. https://doi.org/10.1093/humrep/dead273 .
doi: 10.1093/humrep/dead273
Grynberg M, Mayeur Le Bras A, Hesters L, Gallot V, Frydman N. First birth achieved after fertility preservation using vitrification of in vitro matured oocytes in a woman with breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(4):541–2. https://doi.org/10.1016/j.annonc.2020.01.005 .
doi: 10.1016/j.annonc.2020.01.005
Gayete-Lafuente S, Turan V, Oktay KH. Oocyte cryopreservation with in vitro maturation for fertility preservation in girls at risk for ovarian insufficiency. J Assist Reprod Genet. 2023;40(12):2777–85. https://doi.org/10.1007/s10815-023-02932-7 .
doi: 10.1007/s10815-023-02932-7
pubmed: 37715873
Vuong LN, et al. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. J Assist Reprod Genet. 2020;37(2):347–57. https://doi.org/10.1007/s10815-019-01677-6 .
doi: 10.1007/s10815-019-01677-6
pubmed: 31902102
pmcid: 7056678
Zheng X, et al. In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Hum Reprod Oxf Engl. 2022;37(2):242–53. https://doi.org/10.1093/humrep/deab243 .
doi: 10.1093/humrep/deab243
Rodriguez-Wallberg KA, et al. A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients’ choices and benefit of the chosen methods after long-term follow up. Acta Obstet Gynecol Scand. 2019;98(5):604–15. https://doi.org/10.1111/aogs.13559 .
doi: 10.1111/aogs.13559
pubmed: 30723910
Varlas VN, et al. Social freezing: pressing pause on fertility. Int J Environ Res Public Health. 2021;18(15):8088. https://doi.org/10.3390/ijerph18158088 .
doi: 10.3390/ijerph18158088
pubmed: 34360381
pmcid: 8345795
Luke B, et al. Embryo banking among women diagnosed with cancer: a pilot population-based study in New York, Texas, and Illinois. J Assist Reprod Genet. 2016;33(5):667–74. https://doi.org/10.1007/s10815-016-0669-5 .
doi: 10.1007/s10815-016-0669-5
pubmed: 26843393
pmcid: 4870436
Practice Committee of the American Society for Reproductive Medicine. Electronic address: asrm@asrm.org. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2019;112(6):1022–33. https://doi.org/10.1016/j.fertnstert.2019.09.013 .
doi: 10.1016/j.fertnstert.2019.09.013
Khattak H, et al. Fresh and cryopreserved ovarian tissue transplantation for preserving reproductive and endocrine function: a systematic review and individual patient data meta-analysis. Hum Reprod Update. 2022;28(3):400–16. https://doi.org/10.1093/humupd/dmac003 .
doi: 10.1093/humupd/dmac003
pubmed: 35199164
pmcid: 9733829
Segers I, et al. Live births following fertility preservation using in-vitro maturation of ovarian tissue oocytes. Hum Reprod Oxf Engl. 2020;35(9):2026–36. https://doi.org/10.1093/humrep/deaa175 .
doi: 10.1093/humrep/deaa175
Massarotti C, et al. #ESHREjc report: is OTO-IVM the future fertility preservation alternative for urgent cancer patients? Hum Reprod Oxf Engl. 2021;36(9):2631–3. https://doi.org/10.1093/humrep/deab180 .
doi: 10.1093/humrep/deab180
Fraison E, et al. Live birth rate after female fertility preservation for cancer or haematopoietic stem cell transplantation: a systematic review and meta-analysis of the three main techniques; embryo, oocyte and ovarian tissue cryopreservation. Hum Reprod Oxf Engl. 2023;38(3):Art. no. 3. https://doi.org/10.1093/humrep/deac249 .
doi: 10.1093/humrep/deac249
Colmorn LB, et al. Reproductive and endocrine outcomes in a cohort of Danish women following auto-transplantation of frozen/thawed ovarian tissue from a single center. Cancers. 2022;14(23):5873. https://doi.org/10.3390/cancers14235873 .
doi: 10.3390/cancers14235873
pubmed: 36497354
pmcid: 9740843
Diaz-Garcia C, et al. Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study. Fertil Steril. 2018;109(3):478-485.e2. https://doi.org/10.1016/j.fertnstert.2017.11.018 .
doi: 10.1016/j.fertnstert.2017.11.018
pubmed: 29428307
Liebenthron J, et al. Overnight ovarian tissue transportation for centralized cryobanking: a feasible option. Reprod Biomed Online. 2019;38(5):740–9. https://doi.org/10.1016/j.rbmo.2019.01.006 .
doi: 10.1016/j.rbmo.2019.01.006
pubmed: 30733076
Ott J, et al. Ovarian tissue cryopreservation for non-malignant indications. Arch Gynecol Obstet. 2010;281(4):735–9. https://doi.org/10.1007/s00404-009-1224-8 .
doi: 10.1007/s00404-009-1224-8
pubmed: 19771439
Vaiarelli A, et al. Clinical and laboratory key performance indicators in IVF: a consensus between the Italian Society of Fertility and Sterility and Reproductive Medicine (SIFES-MR) and the Italian Society of Embryology, Reproduction and Research (SIERR). J Assist Reprod Genet. 2023;40(6):1479–94. https://doi.org/10.1007/s10815-023-02792-1 .
doi: 10.1007/s10815-023-02792-1
pubmed: 37093443
pmcid: 10310668
ESHRE Special Interest Group of Embryology and Alpha Scientists in Reproductive Medicine. Electronic address: coticchio.biogenesi@grupposandonato.it. The Vienna consensus: report of an expert meeting on the development of ART laboratory performance indicators. Reprod Biomed Online. 2017;35(5):494–510. https://doi.org/10.1016/j.rbmo.2017.06.015 .
doi: 10.1016/j.rbmo.2017.06.015
Alpha Scientists in Reproductive Medicine. The Alpha consensus meeting on cryopreservation key performance indicators and benchmarks: proceedings of an expert meeting. Reprod Biomed Online. 2012;25(2):146–67. https://doi.org/10.1016/j.rbmo.2012.05.006 .
doi: 10.1016/j.rbmo.2012.05.006
ESHRE Clinic PI Working Group, et al. The Maribor consensus: report of an expert meeting on the development of performance indicators for clinical practice in ART. Hum Reprod Open. 2021;2021(3): hoab022. https://doi.org/10.1093/hropen/hoab022 .
Leung AQ, et al. Clinical outcomes and utilization from over a decade of planned oocyte cryopreservation. Reprod Biomed Online. 2021;43(4):671–9. https://doi.org/10.1016/j.rbmo.2021.06.024 .
doi: 10.1016/j.rbmo.2021.06.024
pubmed: 34474973
Dahhan T, Dancet EAF, Miedema DV, van der Veen F, Goddijn M. Reproductive choices and outcomes after freezing oocytes for medical reasons: a follow-up study. Hum Reprod Oxf Engl. 2014;29(9):1925–30. https://doi.org/10.1093/humrep/deu137 .
doi: 10.1093/humrep/deu137
Devine K, et al. Baby budgeting: oocyte cryopreservation in women delaying reproduction can reduce cost per live birth. Fertil Steril. 2015;103(6):1446-1453.e1-2. https://doi.org/10.1016/j.fertnstert.2015.02.029 .
doi: 10.1016/j.fertnstert.2015.02.029
pubmed: 25813281
pmcid: 4457614
Caughey LE, Lensen S, White KM, Peate M. Disposition intentions of elective egg freezers toward their surplus frozen oocytes: a systematic review and meta-analysis. Fertil Steril. 2021;116(6):1601–19. https://doi.org/10.1016/j.fertnstert.2021.07.1195 .
doi: 10.1016/j.fertnstert.2021.07.1195
pubmed: 34452749
Hawkes K, Smith KR. Do women stop early? Similarities in fertility decline in humans and chimpanzees. Ann N Y Acad Sci. 2010;1204:43–53. https://doi.org/10.1111/j.1749-6632.2010.05527.x .
doi: 10.1111/j.1749-6632.2010.05527.x
pubmed: 20738274
pmcid: 4043631
Menken J, Trussell J, Larsen U. Age and infertility. Science. 1986;233(4771):Art. no. 4771. https://doi.org/10.1126/science.3755843 .
doi: 10.1126/science.3755843
Hendershot GE, Mosher WD, Pratt WF. Infertility and age: an unresolved issue. Fam Plann Perspect. 1982;14(5):Art. no. 5.
doi: 10.2307/2134890
Cobo A, García-Velasco JA, Remohí J, Pellicer A. Oocyte vitrification for fertility preservation for both medical and nonmedicalreasons. Fertil Steril. 2021;115(5):1091–101. https://doi.org/10.1016/j.fertnstert.2021.02.006 .
doi: 10.1016/j.fertnstert.2021.02.006
pubmed: 33933172
Sugai S, Nishijima K, Haino K, Yoshihara K. Pregnancy outcomes at maternal age over 45 years: a systematic review and meta-analysis. Am J Obstet Gynecol MFM. 2023;5(4):100885. https://doi.org/10.1016/j.ajogmf.2023.100885 .
doi: 10.1016/j.ajogmf.2023.100885
pubmed: 36739911
Fouks Y, Sakkas D, Bortoletto PE, Penzias AS, Seidler EA, Vaughan DA. Utilization of cryopreserved oocytes in patients with poor ovarian response after planned oocyte cryopreservation. JAMA Netw Open. 2024;7(1):e2349722. https://doi.org/10.1001/jamanetworkopen.2023.49722 .
doi: 10.1001/jamanetworkopen.2023.49722
pubmed: 38165675
pmcid: 10762568
Hoffman A, et al. Patients’ and Providers’ needs and preferences when considering fertility preservation before cancer treatment: decision-making needs assessment. JMIR Form Res. 2021;5(6):Art. no. 6. https://doi.org/10.2196/25083 .
doi: 10.2196/25083
Drost L, et al. Patients’ and providers’ perspectives on non-urgent egg freezing decision-making: a thematic analysis. BMC Womens Health. 2023;23(1):Art. no. 1. https://doi.org/10.1186/s12905-023-02189-3 .
doi: 10.1186/s12905-023-02189-3